



## Emefcy Group Limited (ASX: EMC) Announces Signing of First African Contract – Expected to Become Key Reference Site for Developing World

June 22, 2016

**Melbourne, Australia and Caesarea, Israel:** The Directors of Emefcy Group Limited (ASX: EMC) are pleased to announce the signing of Emefcy's first African contract for a Membrane Aerated Biofilm Reactor ("MABR")-based wastewater treatment plant for the Ayder Hospital at Mekele University in Tigray, Ethiopia. When complete, the plant will provide an innovative, reliable and low energy wastewater reuse reference site for customers in Africa and throughout the developing world.

The project will, for the first time, provide a high-quality wastewater treatment solution to Mekele University Hospital, which also plans to reuse the treated water for irrigation and toilet flushing on the hospital's grounds. Emefcy's solution was chosen due to its extremely low energy consumption delivering low operating costs, high effluent quality, competitive capital cost, and neighbourhood-friendly design.

Based on the current design specification, the MABR-based system (formerly referred to as "SABRE") will treat 320,000 litres per day, two and a half times the size of Emefcy's wastewater treatment solution at Ha-Yogev in Israel. The contract will generate revenue of approximately A\$430K to Emefcy and is scheduled to be commissioned by the end of this year.

"We expect this first African project to become an excellent reference site for customers in Ethiopia and throughout the developing world. Moreover, the larger treatment capacity of the Mekele University Hospital plant once again confirms Emefcy's competitiveness compared to alternative product offerings for our customers," said Richard Irving, Executive Chairman of Emefcy. "This will become our first international site using an MABR-based system to source irrigation water, thereby offsetting potable water demand in a severely water-stressed region. This booking has enabled us to surpass our 2016 goals of achieving A\$1m in bookings and signing at least two new contracts less than halfway through the year, with more business expected before calendar year end."

"We are excited to sign our first contract in Ethiopia, a country which is currently making major investments in infrastructure and where we perceive a number of potential projects well-suited to Emefcy's technology," said Eytan Levy, CEO of Emefcy. "Ethiopia represents a large opportunity for Emefcy's decentralized MABR-based wastewater treatment solutions, due to its lack of sewage handling infrastructure. Our reliable, energy-efficient, local treatment solution helps avoid massive investment in infrastructure and centralized treatment plants."

Emefcy is partnering with Today-Tomorrow Ventures Inc. (TTV Inc.) a well-connected and well-positioned company in Ethiopia to jointly manage this project and develop future business opportunities.



"We are excited to have teamed up with Emefcy to bring this innovative and highly efficient wastewater treatment system to Ethiopia and in to the Mekele University Hospital. We look forward to this being a true showcase to address the ever growing wastewater treatment and reuse needs of communities all over the country," said Paul Veldman, TTV Managing Partner.

"The Mekele University Hospital is very proud to be the first in Ethiopia to apply an advanced water reuse system as offered by Emefcy for the benefit of the local community," said Kindeya Gebrehiwot (PhD), President and Associate Professor at Mekele University.

### **About Emefcy Group Limited**

Emefcy develops, manufactures and markets new, energy-efficient MABR based wastewater treatment solutions, aiming to change the economics of various markets and addressing the growing global demand for clean water in municipal and industrial plants.

Emefcy's advanced manufacturing facility is equipped with state of the art production machinery, enabling the company to control the quality and meet the quantity requirements of its markets.

With several global innovation awards and a strong scientific background, Emefcy is at the forefront of the next generation of MABR based wastewater treatment. Additional MABR based wastewater solutions out of Emefcy's extensive R&D operations are expected to be announced in the coming year.

Emefcy Group Limited (ASX: EMC) is a public company traded on the Australian Stock Exchange.

Visit our website: [www.emefcy.com](http://www.emefcy.com)

Any forward-looking statements in this announcement are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management.

For further information, please contact:

#### **USA**

Richard Irving, Executive Chairman

E: [richard@emefcygroup.com](mailto:richard@emefcygroup.com) T: +1 408 382 9790

#### **Israel**

Eytan Levy, Managing Director & CEO

E: [eytan@emefcygroup.com](mailto:eytan@emefcygroup.com) T: +972 4-6277555

#### **Australia**

Ross Kennedy, Company Secretary and Advisor to the Board

E: [rossk@emefcygroup.com](mailto:rossk@emefcygroup.com) T: +61 409 524 44